261 related articles for article (PubMed ID: 11962679)
1. Circadian chemotherapy for gynecological and genitourinary cancers.
Kobayashi M; Wood PA; Hrushesky WJ
Chronobiol Int; 2002 Jan; 19(1):237-51. PubMed ID: 11962679
[TBL] [Abstract][Full Text] [Related]
2. [Chronopharmacology and chronotherapy of cancers].
Lévi F
Pathol Biol (Paris); 1996 Sep; 44(7):631-44. PubMed ID: 8977920
[TBL] [Abstract][Full Text] [Related]
3. Cancer chronotherapy: a drug delivery challenge.
Hrushesky WJ
Prog Clin Biol Res; 1990; 341A():1-10. PubMed ID: 2145583
[TBL] [Abstract][Full Text] [Related]
4. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
[TBL] [Abstract][Full Text] [Related]
5. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
6. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
von Roemeling R; Hrushesky WJ
J Clin Oncol; 1989 Nov; 7(11):1710-9. PubMed ID: 2530318
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.
Rajagopalan K; Peereboom D; Budd GT; Olencki T; Murthy S; Elson P; McLain D; Bukowski R
Invest New Drugs; 1998-1999; 16(3):255-8. PubMed ID: 10360605
[TBL] [Abstract][Full Text] [Related]
8. [Chrono-chemotherapy and dose intensity].
Lévi F
Bull Cancer; 1995; 82 Suppl 1():29s-36s. PubMed ID: 7626851
[TBL] [Abstract][Full Text] [Related]
9. Circadian-based infusional FUDR therapy.
Lanning RM; von Roemeling R; Hrushesky WJ
Oncol Nurs Forum; 1990; 17(1):49-56. PubMed ID: 2137216
[TBL] [Abstract][Full Text] [Related]
10. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
[TBL] [Abstract][Full Text] [Related]
11. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Garufi C; Lévi F; Giunta S; Aschelter A; Pace R; Nisticò C; Terzoli E
J Infus Chemother; 1995; 5(3 Suppl 1):134-7. PubMed ID: 8528973
[TBL] [Abstract][Full Text] [Related]
12. Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
Damascelli B; Marchianò A; Frigerio LF; Salvetti M; Spreafico C; Garbagnati F; Zanoni F; Radice F
Cancer; 1991 Sep; 68(5):995-8. PubMed ID: 1833043
[TBL] [Abstract][Full Text] [Related]
13. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Hrushesky WJ; Von Roemeling R; Fraley EE; Rabatin JT
Semin Surg Oncol; 1988; 4(2):110-5. PubMed ID: 2969133
[TBL] [Abstract][Full Text] [Related]
14. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
17. Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
Bjarnason GA; Doyle N; Sone M; Beattie K; Elia J; Owens B
J Infus Chemother; 1995; 5(2):82-8. PubMed ID: 8521240
[TBL] [Abstract][Full Text] [Related]
18. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
[TBL] [Abstract][Full Text] [Related]
19. Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
Ostrow S; Egorin MJ; Hahn D; Markus S; Leroy A; Chang P; Klein M; Bachur NR; Wiernik PH
Cancer; 1980 Oct; 46(8):1715-21. PubMed ID: 7191768
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of urogenital cancers].
Matsumura Y; Tsushima T
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):181-9. PubMed ID: 2041265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
